tirzepatide recent news GROUNDBREAKING UPDATE! FDA has approved TIRZEPATIDE, a pioneering obesity treatment activating GIP & GLP-1 receptors, for weight loss! Previously, has been FDA approved for type 2 diabetes as Mounjaro, and although Tirzepatide Significantly Reduces Mortality and

If half of American adults with obesity started using these drugs, total spending could exceed $411 billion annually more than total 2022 retail prescription drug spending

Weekly dosing works because exposure stays within a predictable band, and consistency is what keeps it there

Yang T, Fang S, Zhang H-X et al (2013) N-3 PUFAs have antiproliferative and apoptotic effects on human colorectal cancer stem-like cells in vitro

The FDA-approved Wegovy and Zepbound titration schedules are starting points, not requirements

Tirzepatide showed a favorable safety profile, with predominantly gastrointestinal adverse effects and a low incidence of hypoglycemia